Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in...
AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and...
AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the...
AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the advancement of its first-in-class...
AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief ...
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.